Vistagen reports positive results for mental fatigue treatment

seekingalpha04-26

Vistagen (NASDAQ:VTGN) reported positive results from a Phase 2a pilot study of its drug candidate PH15 in the improvement of psychomotor impairment caused by mental fatigue. The drug developer said ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2430230279?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1077136596/image_1077136596.jpg","is_english":true,"pubTime":"2024-04-26 02:16","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2430230279","market":"hk","top_or_hot":-1,"title":"Vistagen reports positive results for mental fatigue treatment","media":"seekingalpha","content":"<div>\n<p>Vistagen (NASDAQ:VTGN) reported positive results from a Phase 2a pilot study of its drug candidate PH15 in the improvement of psychomotor impairment caused by mental fatigue.  The drug developer said ...</p>\n\n<a href=\"https://seekingalpha.com/news/4094386-vistagen-reports-positive-results-for-mental-fatigue-treatment\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vistagen reports positive results for mental fatigue treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVistagen reports positive results for mental fatigue treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-26 02:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4094386-vistagen-reports-positive-results-for-mental-fatigue-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vistagen (NASDAQ:VTGN) reported positive results from a Phase 2a pilot study of its drug candidate PH15 in the improvement of psychomotor impairment caused by mental fatigue.  The drug developer said ...</p>\n\n<a href=\"https://seekingalpha.com/news/4094386-vistagen-reports-positive-results-for-mental-fatigue-treatment\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VTGN","symbol_name":"VistaGen Therapeutics, Inc.","start_time":0,"source_url":"https://seekingalpha.com/news/4094386-vistagen-reports-positive-results-for-mental-fatigue-treatment","article_id":"2430230279","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1077136596/image_1077136596.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2430230279","pubTimestamp":1714068968,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Vistagen  reported positive results from a Phase 2a pilot study of its drug candidate PH15 in the improvement of psychomotor impairment caused by mental fatigue.  The drug developer said the study showed PH15, a pherine nasal spray, demonstrated statistically improved reaction time versus placebo or caffeine in sleep-deprived participants. Vistagen added that PH15’s adverse event profile was similar to that of the placebo.   More on VistaGen Therapeutics  Vistagen Therapeutics: A Pipeline With Potential In Anxiety And Depression Vistagen Therapeutics: Initial Analysis Of Fasedienol Points To Bullish Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatments Seeking Alpha’s Quant Rating on VistaGen Therapeutics Historical earnings data for VistaGen Therapeutics","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"VTGN":"VistaGen Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Vistagen报告精神疲劳治疗的积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTGN":1},"content_text":"Vistagen (NASDAQ:VTGN) reported positive results from a Phase 2a pilot study of its drug candidate PH15 in the improvement of psychomotor impairment caused by mental fatigue.  The drug developer said the study showed PH15, a pherine nasal spray, demonstrated statistically improved reaction time versus placebo or caffeine in sleep-deprived participants. Vistagen added that PH15’s adverse event profile was similar to that of the placebo.   More on VistaGen Therapeutics  Vistagen Therapeutics: A Pipeline With Potential In Anxiety And Depression Vistagen Therapeutics: Initial Analysis Of Fasedienol Points To Bullish Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatments Seeking Alpha’s Quant Rating on VistaGen Therapeutics Historical earnings data for VistaGen Therapeutics","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.23.1","shortVersion":"4.23.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2430230279"}